Robust Cell-Based Assays for Detection of Neutralizing Antibodies to Follow on Biologics like Insulin, GLP1 & Avastin
|
|
- Gwendolyn Greer
- 5 years ago
- Views:
Transcription
1 Robust Cell-Based Assays for Detection of Neutralizing Antibodies to Follow on Biologics like Insulin, GLP1 & Avastin Abhi Saharia, Ph. D. Director of Marketing
2 Bioassays in Biologics Development Research Development Marketing Target ID Lead Discovery & Optimization Preclinical Development Clinical Testing & Development Post Release Marketing Discovery, Screening & Lead Identification Lot Release Testing & Stability Studies Neutralizing Antibody Studies
3 Challenges for NAb Assay Development Challenges Extensive assay development Long, multi-step protocol Complex assay Non-specific assay readout Low assay sensitivity Low drug tolerance Specialized instrument required Negative Impact 3-6 months of time Result in 4-6 days Difficulty with precision & transfer Matrix interference High cost & sensitivity of detection Assay interference & sensitivity High cost
4 Agenda EFC Assay Technology NAb Assays with PathHunter EFC Technology GLP1 NAb Assay Insulin NAb Assay Avastin NAb Assay
5 PathHunter Enzyme Fragment Complementation Technology Objectives of PathHunter NAb assays Create single endpoint assays Target early events for target-specific functional response Develop assay with high matrix tolerance Simplify assay protocol Increase sensitivity of NAb assays Increase assay reproducibility Eliminate cell culture as part of the assay
6 Flexibility of the EFC Technology Monitor protein levels degradation or expression Monitor protein translocation nucleus, cytoplasm, early endosome, golgi, membrane
7 Agenda EFC Assay Technology NAb Assays with PathHunter EFC Technology GLP1 NAb Assay Insulin NAb Assay Avastin NAb Assay
8 GLP1 Receptor Agonists : Drugs & Mechanism of Action Exenatide (Byetta/Bydureon), 2005/2012 Lixisenatide (Lyxumia), EU 2013 Liraglutide (Victoza, Saxenda), 2010 Albiglutide (Tanzeum), 2014 Exendin-4 GLP1 (7-37) Existing GLP1R Assays camp ELISA Radio-immuno assay Calcium flux Insulin release assay
9 GLP1 & Exendin-4 Bioassays 30 min
10 GLP1R Assay Specificity
11 GLP1R Assay Reproducibility 3-7% CV for PathHunter Assays Plate to plate (Intra-lot) reproducibility Day to day reproducibility Operator reproducibility High inter-lot reproducibility GLP1R Day to day and Operator Reproducibility Day 1 Operator 1 Day 2 Operator 2 Day 3 Operator 3 Plate 1 Plate 2 Plate 3 Plate 4 Plate 5 Avg %CV EC E E E E E-09 Avg %CV EC E E E E E-09 Avg %CV EC E E E E E-09 Average 2.37nM %RSD 5.53%
12 Agenda EFC Assay Technology NAb Assays with PathHunter EFC Technology GLP1 NAb Assay Insulin NAb Assay Avastin NAb Assay
13 Insulin : Drugs & Mechanism of Action Several insulin drugs on market Rapid Acting Short Acting Intermediate Long Acting Pre-mixed (intermediate & short) Existing assays Glucose uptake Radio Immunoassay Receptor phosphorylation Reporter gene
14 Insulin Bioassay 3 hrs
15 INSR Bioassay Matrix Tolerance Condition EC50 (ng/ml) S:B Ratio 10% NHS % NHS % NHS % NHS
16 INSR NAb Assay Sensitivity Assay conditions 10% human serum Cell seeding = 24 hrs Incubation time = 3 hrs Approximate sensitivity of INSR assay is ng/mL Commercially Developed anti-insulin antibody
17 Agenda EFC Assay Technology NAb Assays with PathHunter EFC Technology GLP1 NAb Assay Insulin NAb Assay Avastin NAb Assay
18 Anti-VEGF Antibody : Drugs & MOA Existing assay HUVEC proliferation assay
19 Bevacizumab (Avastin ) Bioassay
20 R L U R L U Robust & Reproducible Bevacizumab Assay V E G F R 2 D im e r iz a tio n B io a s s a y (H E K ) V E G F R 2 D im e r iz a tio n B io a s s a y (H E K ) P la te A v a s tin P la te 2 P la te V E G F V E G F [g /m L ] A v a s tin [g /m L ] n g /m l V E G F HillSlope EC50 Plate e-009 S /B 4.8 Plate e-009 Plate e HillSlope EC50 Avastin e-008 S /B VEGF e-009
21 R L U Assay Specificity & Matrix Tolerance Assay Specificity Matrix Tolerance K D R / K D R (H E K ) V E G F V E G F V E G F B V E G F C Condition EC50 (ng/ml) S:B Ratio 10% NHS % NHS % NHS L ig a n d [g /m L ] 74% NHS % NHS
22 Anti-Bevacizumab Neutralizing Antibody EC50 of Anti-Avastin Antibody = 470 ng/ml Approximate sensitivity of assay = ng/ml
23 RLU Anti-Bevacizumab Neutralizing Antibody Assay VEGF only 0 Anti-Avastin (ng/ml) 0 A B 0 33 F 100 E 300 D 900 C VEGF Series1 (EC80) Avastin (ND50) KDR/KDR BioAssay VEGF+ Avastin VEGF + Avastin + anti-avastin Samples prepared in 10% pooled normal human serum
24 Summary Objectives for PathHunter NAb assays Create single endpoint assays Target early events for target-specific functional response Develop assay with high matrix tolerance Simplify assay protocol Increase sensitivity of NAb assays Increase assay reproducibility Eliminate cell culture
25 R L U R L U R L U RLU Thaw & Use Bioassay Cells Live Culture Assay Frozen Thaw & Use Assay IL 5 R A / C S F 2 R B A s s a y IL5RA / CSF2RB Assay S/B: 4.6 E C -5 0 : p M S/B: 4.9 EC-50: 342pM Advantages of single use cells Avoid cell culture & associated variability Controlled propagation & harvest Controlled passage number Consistent performance on thaw Requires controlled two-tier banking Save time and money Get more reproducible results IL -5 [g /m L ] Er yth ropoiet i n A ssay S /B : E C -5 0 : p M E ry th ro p o ie tin [M ] E r y th r o p o ie tin A s s a y S /B : 6.1 E C -5 0 : p M IL-5 [M] E ry th ro p o ie tin [M ]
26 Cell Bank Characterization Three-tiered cell banking Controlled cell culture Controlled harvest Cell viability post thaw and pre-thaw Freezing process Sterility and mycoplasma Intra-lot reproducibility
27 Application of EFC Bioassays Biosimilar Bioassay Kit Cell Line Insulin Lispro Bioassay Kit Developed Developed Insulin Glargine Bioassay Kit Developed Developed Insulin Bioassay Kit Developed Developed Exendin-4 Bioassay Kit Developed Developed GLP1 Bioassay Kit Developed Developed GLP1 (7-37) Bioassay Kit Developed Developed Epoetin Alfa Bioassay Kit Developed Developed Darbepoetin Alfa Bioassay Kit Developed Developed Ranibizumab Bioassay Kit Developed Developed Aflibercept Bioasay Kit Developed Developed Bevacizumab Bioassay Kit Developed Developed Ustekinumab Bioassay Kit * Developed Growth Hormone Bioassay Kit * Developed G-CSF Bioassay Kit * Developed Glucagon Bioassay Kit * Developed Denosumab Bioassay Kit * Developed FSH Bioassay Kit * Developed PTH Bioassay Kit * Developed LH/hCG Bioassay Kit * Developed Infliximab Bioassay Kit * Developed Golimumab Bioassay Kit * Developed Etanercept Bioassay Kit * Developed Certolizumab pegol Bioassay Kit * Developed Adalimumab Bioassay Kit * Developed GHRH Bioassay Kit * Developed Anakinra Bioassay Kit * Developed Canakinumab Bioassay Kit * Developed Additional assays under development Tocilizumab Panitumumab Cetuximab 750+ bioassays for novel targets GPCRs Receptor Kinases TGFβ Receptor Superfamily Interleukin & Cytokine Receptors * Thaw and use bioassay cells are under development
Controlling cell-based bioassay performance through controlled preparation of bioassayready
Controlling cell-based bioassay performance through controlled preparation of bioassayready cells Teresa Surowy September 2013 Promega Corporation Introduction The importance of cell-based bioassays and
More informationADCC Reporter Bioassays - V and F Variants:
ADCC Reporter Bioassays - V and F Variants: Novel, Bioluminescent Cell-Based Assays for Quantifying Fc Effector Function of Antibodies Promega Corporation April 2014 Rev 01 Topics Presented Introduction
More informationBioactivity Assays: Putting the Puzzle Together
Bioactivity Assays: Putting the Puzzle Together Dr. Ulrike Herbrand Department for Biosafety & Bioassay Services Charles River Biologics Testing Solutions Outline General Remarks MoA reflecting bioassays
More informationExendin-4 (Exenatide) ELISA Kit
Exendin-4 (Exenatide) ELISA Kit Catalog: DEIABL227 For the quantitative determination of Exendin-4 in serum or plasma using competitive ELISA method For Research Use Only. Protocol Provided for Informational
More informationMCP uL 25uL 25uL 25uL Typical Dilution 1:2 None None None Manufacturer Defined Minimum Detectible Concentration
Units: pg/ml pg/ml pg/ml pg/ml Assay Name RnD Systems Millipore Magnetic Hormone ELISA Adipokine Panel 2 Panel Catalog Number DCP HADK2MAG-61K HCYTOMAG-6K HMHMAG-34K EGF, FGF-2, Eotaxin, TGF-a, G-CSF,
More informationBeyond A1C. Non-glycemic Effects of GLP-1 Receptor Agonists. Olga Astapova MD, PhD Luis Chavez MD URMC Endocrinology Fellows
Beyond A1C Non-glycemic Effects of GLP-1 Receptor Agonists Olga Astapova MD, PhD Luis Chavez MD URMC Endocrinology Fellows Disclosures No conflicts of interest. Learning Objectives 1. Understand the physiological
More informationDKK-1 ELISA, Cat.No. BI For the quantitative determination of DKK-1 in human serum
DKK-1 ELISA, Cat.No. BI-20413 For the quantitative determination of DKK-1 in human serum ASSAY CHARACTERISTICS Method Standard range Conversion factor Sample volume / well Incubation time, temp. Sensitivity
More informationGLP-2 ELISA. For the quantitative determination of GLP-2 in human serum and plasma samples.
GLP-2 ELISA For the quantitative determination of GLP-2 in human serum and plasma samples. For Research Use Only. Not For Use In Diagnostic Procedures. Catalog Number: 48-GP2HU-E01.1 Size: 96 wells Version:
More informationBioassays for Quality Control of Cell & Gene Therapy Products
Bioassays for Quality Control of Cell & Gene Therapy Products Erik Rutjens, Cell & Gene Therapy, Novartis Pharma AG CASSS Bioassays, Silver Spring, March2015 CTL019 Introduction CARTs = Chimeric Antigen
More informationReporter Gene Immunotherapy Bioassays
Reporter Gene Immunotherapy Bioassays Expand the Tool Box for Drug Development in Individual and Combination Immunotherapy Jey Cheng, Ph.D. 215. BEBPA Bioassay Conference September 3, 216 Presentation
More informationGLP-2 (Rat) ELISA. For the quantitative determination of glucagon-like peptide 2 (GLP-2) in rat serum and plasma
GLP-2 (Rat) ELISA For the quantitative determination of glucagon-like peptide 2 (GLP-2) in rat serum and plasma For Research Use Only. Not For Use In Diagnostic Procedures. Catalog Number: 48-GP2RT-E01
More informationNovel drug developed to treat type 2 diabetes are neuroprotective Alzheimer s disease
Novel drug developed to treat type 2 diabetes are neuroprotective Alzheimer s disease Prof. Christian Hölscher, PhD Biomed and Life Sciences Faculty of Health and Medicine Lancaster University, UK Alzheimer
More informationGLP-1 agonists. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
GLP-1 agonists Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What do GLP-1 agonists do? Physiology of postprandial glucose regulation Meal ❶ ❷ Insulin Rising plasma
More informationGFP Assays
GFP Assays 2009-07-03 GFP Assays Akt1 SMAD2 STAT3 NFAT-C1 MAPKAP-k2 Rac-1 PLCδ PH domain FYVE G2M CCPM Cell survival, proliferation, apoptosis, insulin response pathways TGF-beta signalling, growth, differentiation,
More informationMouse GLP-2 EIA FOR LABORATORY USE ONLY
YK142 Mouse GLP-2 EIA FOR LABORATORY USE ONLY Kasumigaseki place, 3-6-7, Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan http://www.sceti.co.jp/english/export e-mail exp-pet@sceti.co.jp
More informationIdentification of GLP1R agonists using a novel high throughput screening assay Wan Namkung, Ph.D.
Identification of GLP1R agonists using a novel high throughput screening assay Wan Namkung, Ph.D. College of Pharmacy, Yonsei University Contents High-throughput screening (HTS) HTS assays for identification
More informationMouse GLP-2 EIA. Cat. No. KT-374. For the quantitative determination of GLP-2 in mouse serum or plasma. For Research Use Only. 1 Rev.
Mouse GLP-2 EIA For the quantitative determination of GLP-2 in mouse serum or plasma. Cat. No. KT-374 For Research Use Only. 1 Rev. 11357374 PRODUCT INFORMATION Mouse GLP-2 EIA Cat. No. KT-374 INTENDED
More informationDrug Name. J0129 Injection, abatacept (Orencia ), 10 mg Effective 01/01/2014. J0178 Injection, aflibercept (Eylea ), 1 mg Effective 04/01/2015
J0129 Injection, abatacept (Orencia ), 10 J0178 Injection, aflibercept (Eylea ), 1 J0256 J0257 J0585 J0586 J0587 J0588 J0597 J0641 J0717 J0800 Injection, alpha 1-proteinase inhibitor, human (Aralast NP,
More informationType 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions
Diabetes Mellitus: Complications and Co-Morbid Conditions ADA Guidelines for Glycemic Control: 2016 Retinopathy Between 2005-2008, 28.5% of patients with diabetes 40 years and older diagnosed with diabetic
More informationBIOASSAYS IN PRODUCT DEVELOPMENT: An Immuno-Oncology Perspective
BIOASSAYS IN PRODUCT DEVELOPMENT: An Immuno-Oncology Perspective CASSS Bioassays May 09, 2017 Tara Stauffer 1 Overview Introduction: Cell-based bioassays in IO product development Immuno-Oncology (IO)
More informationTable 1. Preparation of calibrators and controls Infliximab Adalimumab Etanercept Golimumab Certolizumab pegol Calibrator/ control
This application note contains a suggested protocol and performance data. Each individual laboratory must set up their own method and perform relevant validations. For research and professional use only.
More informationINJECTABLE THERAPY FOR THE TREATMENT OF DIABETES
INJECTABLE THERAPY FOR THE TREATMENT OF DIABETES ARSHNA SANGHRAJKA DIABETES SPECIALIST PRESCRIBING PHARMACIST OBJECTIVES EXPLORE THE TYPES OF INSULIN AND INJECTABLE DIABETES TREATMENTS AND DEVICES AVAILABLE
More informationCanine Insulin ELISA Kit
Canine Insulin ELISA Kit Cat. No.:DEIA2033 Pkg.Size:96T Intended use This product provides a method for the quantitative determination of insulin in canine serum and plasma. General Description Insulin
More informationThe Death of Sulfonylureas? A Review of New Diabetes Medications
The Death of Sulfonylureas? A Review of New Diabetes Medications Kelly Hoenig, Pharm.D., BCPS Cedar Rapids Family Medicine Residency 2/4/17 Objectives Review GLP-1 Agonists, DPP-IV Inhibitors and SGLT-2
More informationValidation & Assay Performance Summary
Validation & Assay Performance Summary LanthaScreen IGF-1R GripTite Cells Cat. no. K1834 Modification Detected: Phosphorylation of Multiple Tyr Residues on IGF-1R LanthaScreen Cellular Assay Validation
More informationTYP 2 DIABETES. Marc Donath
TYP 2 DIABETES Marc Donath Treatment of Typ 2 Diabetes GLP-1 Anti-IL-1β Insulin sulfonylureas Metformin UCP-1 IL-1β Sport SGLT2i Bariatric surgery Cardiomyocytes Control Glucose Dyntar et al. Diabetes
More informationManagement of Type 2 Diabetes Mellitus. Heather Corn, MD, MS Endocrinology, Diabetes, and Metabolism
Management of Type 2 Diabetes Mellitus Heather Corn, MD, MS Endocrinology, Diabetes, and Metabolism Disclosures Working for Intermountain Healthcare Some of the views represented are the opinion of ABIM-certified
More informationHuman Obestatin ELISA
K-ASSAY Human Obestatin ELISA For the quantitative determination of obestatin in human serum and plasma Cat. No. KT-495 For Research Use Only. 1 Rev. 081309 K-ASSAY PRODUCT INFORMATION Human Obestatin
More informationUpdate Diabetes Therapie. Marc Y Donath
Update Diabetes Therapie Marc Y Donath Recent CV outcome studies in Diabetes N Engl J Med. 2015 373:2117-28 (Empa-Reg outcome study) N Engl J Med. 2016 June 13 (LEADER trial) N Engl J Med. 2017 June 12
More informationInsulin Initiation and Intensification. Disclosure. Objectives
Insulin Initiation and Intensification Neil Skolnik, M.D. Associate Director Family Medicine Residency Program Abington Memorial Hospital Professor of Family and Community Medicine Temple University School
More informationGLP-1 receptor agonists for type 2 diabetes currently available in the U.S.
GLP-1 receptor agonists for type 2 diabetes currently available in the U.S. GLP-1 agonists are a class of antidiabetic agents that mimic the actions of the glucagon-like peptide. GLP-1 is one of several
More informationMouse GLP-2 ELISA Kit
Package Insert Mouse GLP-2 ELISA Kit Catalog Number: YK142 (1 x 96 wells) For Research Use Only. Not for use in diagnostic procedures. v. 1.0 Eagle Biosciences, Inc. 20A Northwest Blvd., Suite 112, Nashua,
More informationI. Introduction. II. Characteristics
YK050 Rat Leptin ELISA I. Introduction Leptin, which is a product of ob gene, is a protein consisting of 167 amino acids and it is secreted from white adipose tissue. It is known that leptin acts on hypothalamus
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC)
DERBYSHIRE JOINT AREA PRERIBING COMMITTEE (JAPC) Derbyshire commissioning guidance on biologic drugs f the treatment of Rheumatoid arthritis with methotrexate This algithm is a tool to aid the implementation
More informationGamma-aminobutyric acid (GABA) treatment blocks inflammatory pathways and promotes survival and proliferation of pancreatic beta cells
Gamma-aminobutyric acid (GABA) treatment blocks inflammatory pathways and promotes survival and proliferation of pancreatic beta cells Gérald J. Prud homme, MD, FRCPC Keenan Research Centre for Biomedical
More information6/1/2018. Lou Haenel, IV, DO, FACE, FACOI Endocrinology Roper St Francis Charleston, SC THE OMINOUS OCTET: HOW PATHOPHYSIOLOGY AND THERAPY MERGE
Lou Haenel, IV, DO, FACE, FACOI Endocrinology Roper St Francis Charleston, SC THE OMINOUS OCTET: HOW PATHOPHYSIOLOGY AND THERAPY MERGE 1 2 3 Sulfonylureas Glipizide Glyburide Glimeperide 4 Metformin Gold
More informationGLUCAGON LIKE PEPTIDE (GLP) 1 AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES, WEIGHT CONTROL AND CARDIOVASCULAR PROTECTION.
GLUCAGON LIKE PEPTIDE (GLP) 1 AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES, WEIGHT CONTROL AND CARDIOVASCULAR PROTECTION. Patricia Garnica MS, ANP-BC, CDE, CDTC Inpatient Diabetes Nurse Practitioner North
More informationWhat s New in Diabetes Medications. Jena Torpin, PharmD
What s New in Diabetes Medications Jena Torpin, PharmD 1 Objectives Discuss new medications in the management of diabetes Understand the mechanism of the medications discussed Understand the side effects
More informationMercodia Equine Insulin ELISA
Mercodia Equine Insulin ELISA Directions for Use 10-1205-01 REAGENTS FOR 96 DETERMINATIONS Manufactured by Mercodia AB Sylveniusgatan 8A SE-754 50 Uppsala Sweden EXPLANATION OF SYMBOLS USED ON LABELS =
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 21 September 2006 EMEA/CHMP/BWP/298390/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON
More informationNew tools bring greater understanding to cellular metabolism research
New tools bring greater understanding to cellular metabolism research Mourad Ferhat, Ph.D, 7 Juin 2017 FDSS Users Meeting, Hamamatsu mourad.ferhat@promega.com Today s talk : focus on new cell-based assays
More informationAlphaScreen : A Straightforward and Powerful Alternative to ELISA. Martina Bielefeld-Sévigny Ph.D., R&D Director
AlphaScreen : A Straightforward and Powerful Alternative to ELISA Martina Bielefeld-Sévigny Ph.D., R&D Director Overview AlphaScreen - an alternative to ELISA Why an alternative to ELISA? Assay principle
More informationProvider Administered Drug Program (PADP) and Physician Administered Drug VPSS List
Provider Administered Drug Program (PADP) and Physician Administered Drug VPSS List Code Drug Name Effective and/or Term Date J0129 Injection, abatacept (Orencia ), 10 mg J0178 Injection, aflibercept (Eylea
More informationYK052 Mouse Leptin ELISA
YK052 Mouse Leptin ELISA FOR LABORATORY USE ONLY YANAIHARA INSTITUTE INC. 2480-1 AWAKURA, FUJINOMIYA-SHI SHIZUOKA, JAPAN 418-0011 Contents Ⅰ. Introduction 2 Ⅱ. Characteristics 3 Ⅲ. Composition 4 Ⅳ. Method
More informationFOR LABORATORY USE ONLY
YK060 Insulin ELISA FOR LABORATORY USE ONLY Kasumigaseki Place, 3-6-7, Kasumigaseki, Chiyoda-ku Tokyo 100-0013 Japan URL: http://www.sceti.co.jp/export/ e-mail: medical@sceti.co.jp Contents
More informationRat Leptin-HS ELISA FOR LABORATORY USE ONLY YANAIHARA INSTITUTE INC AWAKURA, FUJINOMIYA - SHI SHIZUOKA, JAPAN
YK051 Rat Leptin-HS ELISA FOR LABORATORY USE ONLY YANAIHARA INSTITUTE INC. 2480-1 AWAKURA, FUJINOMIYA - SHI SHIZUOKA, JAPAN 418 0011 Contents Introduction 2 Characteristics 3 Composition 4 Method 5-6 Notes
More informationHelp the Heart. An Update on GLP-1 Agonists and SGLT2 Inhibitors. Tara Hawley, PharmD PGY1 Pharmacy Resident Mayo Clinic Health System Eau Claire
Help the Heart An Update on GLP-1 Agonists and SGLT2 Inhibitors Tara Hawley, PharmD PGY1 Pharmacy Resident Mayo Clinic Health System Eau Claire Mayo Clinic Grand Rounds May 16, 2017 2017 MFMER slide-1
More informationRHEUMATOID ARTHRITIS DRUGS
Rheumatology Biologics Criteria from the Exceptional Access Program RHEUMATOID ARTHRITIS DRUGS DRUG NAME BRS REIMBURSED DOSAGE FORM/ STRENGTH Adalimumab Humira 40 mg/0.8 syringe and 40mg/0.8 pen for Anakinra
More informationⅠ.Introduction. Ⅱ.Characteristics
YK090 Rat/Human Glucagon EIA kit Ⅰ.Introduction According to many studies on glucagon immunoassay, it has been established that the antibody against the C - terminal fragment ( 19 29 ) of glucagon has
More informationVEGF Bioassay Instructions for use of Product GA2001 and GA2005
TECHNICAL MANUAL VEGF Bioassay Instructions for use of Product GA21 and GA25 9/18 TM544 VEGF Bioassay All technical literature is available at: www.promega.com/protocols/ Visit the web site to verify that
More informationThe Adiponectin Turbidimetric Immunoassay Reagent Kit
The Adiponectin Turbidimetric Immunoassay Reagent Kit Catalogue number: 51010 For the quantitative determination of Adiponectin in human serum and plasma This package insert must be read in its entirety
More informationPERIOSTIN ELISA CONTENTS
PERIOSTIN ELISA for the quantitative determination of Periostin in human serum, EDTA plasma, heparin plasma, and citrate plasma Cat. No. BI-20433. 12 x 8 tests CONTENTS ASSAY CHARACTERISTICS Summary...
More informationGoals and Challenges of Communication. Communication and Signal Transduction. How Do Cells Communicate?
Goals and Challenges of Communication Reaching (only) the correct recipient(s) Imparting correct information Timeliness Causing the desired effect Effective termination Communication and Signal Transduction
More informationIncredible Incretins Abby Frye, PharmD, BCACP
Incredible Incretins Abby Frye, PharmD, BCACP Objectives & Disclosures Review the pathophysiology of T2DM and the impact of the incretin system Describe the defining characteristics of the available glucagonlike
More informationDIABETES - FACT SHEET
DIABETES - FACT SHEET What is diabetes? Diabetes mellitus, often shortened to diabetes, is a chronic condition that affects the body's ability to control blood sugar level and use energy from food. In
More informationBovine Insulin ELISA
Bovine Insulin ELISA For quantitative determination of insulin in bovine serum and plasma. For Research Use Only. Not For Use In Diagnostic Procedures. Catalog Number: 80-INSBO-E01 Size: 96 wells Version:
More informationMouse C-peptide EIA. Cat. No. YII-YK013-EX FOR LABORATORY USE ONLY
Mouse C-peptide EIA Cat. No. YII-YK013-EX FOR LABORATORY USE ONLY TOYO 2CHOME, KOTO-KU, TOKYO, 135-0016, JAPAN http://www.cosmobio.co.jp e-mail : export@cosmobio.co.jp Phone : +81-3-5632-9617 FAX : +81-3-5632-9618
More informationNovel Reporter Gene Bioassays for Immunotherapy Drug Research and Development Jey Cheng, PhD Sr Research Scientist Promega Corporation
Novel Reporter Gene Bioassays for Immunotherapy Drug Research and Development Jey Cheng, PhD Sr Research Scientist 215 Outline Immune Checkpoint and Combination Therapies Reporter Gene Bioassays: Design,
More informationPorcine/Canine Insulin ELISA
Porcine/Canine Insulin ELISA For the quantitative determination of insulin in porcine or canine serum and plasma. Please read carefully due to Critical Changes, e.g., Calculation of Results. For Research
More informationBNP Fragment EIA (Cat.No. BI-20852W) For the Determination of BNP Fragment in Human Samples
BNP Fragment EIA (Cat.No. BI-20852W) For the Determination of BNP Fragment in Human Samples ASSAY CHARACTERISTICS Method Competitive Enzyme Immunoassay, HRP/TMB. Microtiter plates are coated with a polyclonal
More informationInsulin (Porcine/Canine) ELISA
Insulin (Porcine/Canine) ELISA For the quantitative measurement of insulin in Porcine/Canine serum and plasma (EDTA) For Research Use Only. Not For Use In Diagnostic Procedures. Catalog Number: 80-INSPO-E01
More informationThe first stop for professional medicines advice
London Medicines Evaluation Network Overview: Glucagon-Like Peptide-1 receptor analogues The first stop for professional medicines advice 1 London Medicines Evaluation Network Overview: Glucagon-Like Peptide-1
More informationRat Leptin ELISA FOR LABORATORY USE ONLY YANAIHARA INSTITUTE INC AWAKURA, FUJINOMIYA - SHI SHIZUOKA, JAPAN
YK050 Rat Leptin ELISA FOR LABORATORY USE ONLY YANAIHARA INSTITUTE INC. 2480-1 AWAKURA, FUJINOMIYA - SHI SHIZUOKA, JAPAN 418-0011 Contents Introduction 2 Characteristics 3 Composition 4 Method 5-6 Notes
More informationREFERENCE CODE GDHC497DFR PUBLICAT ION DATE DECEMBER 2014 ORENCIA (ABATACEPT) (RHEUMATOID ARTHRITIS) - FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC497DFR PUBLICAT ION DATE DECEMBER 2014 ORENCIA (ABATACEPT) (RHEUMATOID ARTHRITIS) - Executive Summary The table below provides the key metrics for Orencia (abatacept) in the 10MM (US,
More informationInstructions for use. TSH rat ELISA. Please use only the valid version of the Instructions for Use provided with the kit AR E-8600
Instructions for use TSH rat ELISA AR E-8600 TSH rat ELISA 1. INTRODUCTION 1.1 Intended use The TSH rat ELISA is an enzyme immunoassay for the quantitative measurement of TSH in rat serum. For research
More informationIntroduction to Peptides. Edwin Lee, M.D., F.A.C.E. Institute for Hormonal Balance Orlando, FL
Introduction to Peptides Edwin Lee, M.D., F.A.C.E. Institute for Hormonal Balance Orlando, FL Disclosure The following potential conflict of interest relationships are germane to my presentation. Equipment:
More informationPharmacology Updates. Quang T Nguyen, FACP, FACE, FTOS 11/18/17
Pharmacology Updates Quang T Nguyen, FACP, FACE, FTOS 11/18/17 14 Classes of Drugs Available for the Treatment of Type 2 DM in the USA ### Class A1c Reduction Hypoglycemia Weight Change Dosing (times/day)
More informationEndocrine pharmacology (3)
بسم رلا هللا Endocrine pharmacology (3) Natural hormone characterized by short of action : a lot of them ineffective orally ( for example ), but when we give it from outside it enters the body exactly
More informationRat Glicentin EIA FOR RESEARCH USE ONLY. <Distributed by> DF Kasumigaseki Place, 3-6-7, Kasumigaseki, Chiyoda-ku Tokyo Japan
YK111 Rat Glicentin EIA FOR RESEARCH USE ONLY DF Kasumigaseki Place, 3-6-7, Kasumigaseki, Chiyoda-ku Tokyo 100-0013 Japan URL: http://www.sceti.co.jp/export/ e-mail: exp-pet@sceti.co.jp
More informationREFERENCE CODE GDHC496DFR PUBLICAT ION DATE DECEMBER 2014 CIMZIA (CERTOLIZUMAB PEGOL) (RHEUMATOID ARTHRITIS) - FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC496DFR PUBLICAT ION DATE DECEMBER 2014 CIMZIA (CERTOLIZUMAB PEGOL) (RHEUMATOID ARTHRITIS) - Executive Summary The table below provides the key metrics for Cimzia (certolizumab pegol)
More informationAchieving and maintaining good glycemic control is an
Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE; Kathleen Wyne, MD, PhD, FACE, FNLA; Anthony Cannon,
More informationMedical therapy advances London/Manchester RCP February/June 2016
Medical therapy advances London/Manchester RCP February/June 2016 Advances in medical therapies for diabetes mellitus Duality of interest: The speaker or institutions with which he is associated has received
More informationREFERENCE CODE GDHC509DFR PUBLICAT ION DATE DECEMBER 2014 MAVRILIMUMAB (RHEUMATOID ARTHRITIS) FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC509DFR PUBLICAT ION DATE DECEMBER 2014 MAVRILIMUMAB (RHEUMATOID ARTHRITIS) Executive Summary The table below presents the key metrics for Mavrilimumab in the 10MM Rheumatoid Arthritis
More informationGlucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol
Glucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed
More informationREFERENCE CODE GDHC501DFR PUBLICAT ION DATE DECEMBER 2014 XELJANZ (TOFACITINIB) (RHEUMATOID ARTHRITIS) - FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC501DFR PUBLICAT ION DATE DECEMBER 2014 XELJANZ (TOFACITINIB) (RHEUMATOID ARTHRITIS) - Executive Summary The table below provides the key metrics for Xeljanz (tofacitinib) in the 10MM
More informationLet s not sugarcoat it! Update on Pharmacologic Management of Type II DM
Let s not sugarcoat it! Update on Pharmacologic Management of Type II DM Gregory Castelli, PharmD, BCPS, BC-ADM Clinical Pharmacist UPMC St. Margaret Objectives By the end of this presentation, participants
More informationNori Rabbit IL-2 ELISA Kit DataSheet
Nori Rabbit IL-2 ELISA Kit DataSheet IL-2 is an interleukin, a type of cytokine immune system signaling molecule. IL-2 is a T cell stimulatory cytokine best known for inducing T cell proliferation, the
More informationHyaluronan Quantification Kit
Product manual (ELISA-like assay for HA / Hyaluronic Acid) Updated on Jan. 6th, 207 - Background Hyaluronan (HA) is an unbranched glycosaminoglycan composed of repeating disaccharide units of D-glucronic
More informationLIST OF FIGURES INTRODUCTION
SUPPLEMENT: 2017 INTRODUCTION This document is a supplement to the PMPRB publication Market Intelligence Report: Biologic Response Modifier Agents, 2015 1 produced under the NPDUIS initiative. The supplement
More informationMaking Sense of New DM Therapies and Technologies
Making Sense of New DM Therapies and Technologies Sandra Indacochea Sobel, MD Clinical Assistant Professor of Medicine Clinical Chief of Endocrinology, UPMC Mercy Division of Endocrinology, Diabetes, and
More informationEndo 2 SLO Practice (online) Page 1 of 7
Endo 2 SLO Practice (online) Page 1 of 7 1. A long- acting insulin, like Lantus is for? A. When the next meal is within 30-60 minutes of the injection B. Over night use or for ½ of the day often combined
More informationWhat the Pill Looks Like. How it Works. Slows carbohydrate absorption. Reduces amount of sugar made by the liver. Increases release of insulin
Diabetes s Oral s - Pills These are some of the pills that are currently available in Canada to treat diabetes. Each medication has benefits and side effects you should be aware of. Your diabetes team
More informationIV2-113E Use by. Invitron Glargine ELISA Kit REF LOT IVD. Definitions. English. For in-vitro diagnostic use. Instructions for use.
Definitions Instructions for use REF Catalogue number IV2-113E Use by English Invitron Glargine ELISA Kit For in-vitro diagnostic use Σ 96 LOT IVD Lot/Batch Code Storage temperature limitations In vitro
More informationRat Insulin ELISA. For the quantitative determination of insulin in rat serum and plasma. For Research Use Only. Not For Use In Diagnostic Procedures.
Rat Insulin ELISA For the quantitative determination of insulin in rat serum and plasma For Research Use Only. Not For Use In Diagnostic Procedures. Catalog Number: Size: 80-INSRT-E01, E10 96 wells, 10
More informationEli Lilly and Company Investment Community Meeting
Eli Lilly and Company Investment Community Meeting October 3, 2013 8:30 a.m. 12:30 p.m. Safe Harbor Provision This presentation contains forward-looking statements that are based on management's current
More informationHbA1c (Human) ELISA Kit
HbA1c (Human) ELISA Kit Cat. No.:DEIA3509 Pkg.Size:96T Intended use GHbA1c (Human) ELISA Kit is a sandwich enzyme immunoassay for the quantitative measurement of human GHbA1c. General Description vhemoglobin,
More informationSupplementary Materials for
www.sciencesignaling.org/cgi/content/full/6/305/ra106/dc1 Supplementary Materials for Controlling Long-Term Signaling: Receptor Dynamics Determine Attenuation and Refractory Behavior of the TGF-β Pathway
More informationDiabetes Update: Intensifying Insulin Therapy Nuts, Bolts and Other Items
Diabetes Update: Intensifying Insulin Therapy Nuts, Bolts and Other Items Hayley A. Miller, MD Physician, Internal Medicine, Diabetes and Metabolism, Sandy Clinic, Intermountain Healthcare Objectives:
More informationTechnology appraisal guidance Published: 9 August 2017 nice.org.uk/guidance/ta466
Baricitinib for moderate to severeere rheumatoid arthritis Technology appraisal guidance Published: 9 August 2017 nice.org.uk/guidance/ta466 NICE 2017. All rights reserved. Subject to Notice of rights
More informationVedolizumab Drug Level ELISA
Vedolizumab Drug Level ELISA For the quantitative determination of free Entyvio concentration in human serum and EDTA plasma. Please read carefully due to Critical Changes, e.g., Updates to specificity
More informationCurrent and future market dynamics overview
OVERVIEW Catalyst Summary EXECUTIVE SUMMARY Strategic scoping and focus Datamonitor key findings Related reports MARKET DEFINITION Published diabetes reports Market definition for antidiabetic drugs Forecast
More informationNICE TA Adherence Check List
NICE TA Adherence Check List KEY NICE TA PAS Not Terminated Indication Technology Appraisal carried out by the National Institute of Clinical Excellence - It is the process by which new and existing drugs
More informationInjectable Therapies in Diabetes
Injectable Therapies in Diabetes Diabetes Specialist Nurse Linda Burns Learning Outcomes Understand the place of injectible therapies in diabetes Understand when patients may require insulin therapy Consider
More informationThe Alphabet Soup of Diabetes. Egils Bogdanovics M.D. Hungerford Diabetes Center
The Alphabet Soup of Diabetes Egils Bogdanovics M.D. Hungerford Diabetes Center Insulin: January 11, 1922 12 year old Leonard Thompson, on a starvation diet for 2 years received his first insulin injection
More informationInjectable GLP 1 therapy: weight loss effects seen in obesity with and without diabetes
Injectable GLP 1 therapy: weight loss effects seen in obesity with and without diabetes Dr Masud Haq Consultant Lead in Diabetes & Endocrinology Maidstone & Tunbridge Wells NHS Trust & The London Preventative
More informationDog Insulin ELISA Kit (TMB)
Dog Insulin ELISA Kit (TMB) Research Reagent [Advantage] Please, read this instruction carefully before use. (1) Dog Insulin Kit is a high speed EIA. (for 3-4 hours). (2) Dog Insulin Kit can measure in
More informationPRODUCT LIST 2011 Immunoassays RIA, IRMA, REA
PRODUCT LIST 2011 Immunoassays RIA, IRMA, REA REPRODUCTIVE ANDROGENS Androstanediol glucuronide DSL9200 RIA CT 100 185 Androstenedione IM0674 RIA CT 100 185 Androstenedione DSL3800 RIA CT 100 185 DHEA
More information25(OH) Vitamin D ELISA (BD-220BA), 192 Tests
INTENDED USE The 25-hydroxy (25-OH) Vitamin D ELISA is intended for the quantitative determination of total 25-OH Vitamin D in human serum and Plasma. SUMMARY AND EXPLANATION Vitamin D is a steroid hormone
More informationInformation for Patients
Information for Patients Guidance for Diabetic Persons having an OGD or Bronchoscopy This guidance is provided to assist with your preparation for your endoscopic procedure. If you feel unclear about how
More informationBRISTOL-MYERS SQUIBB and ASTRAZENECA v SANOFI
CASE AUTH/2638/9/13 and AUTH/2639/9/13 BRISTOL-MYERS SQUIBB and ASTRAZENECA v SANOFI Promotion of Lyxumia Bristol-Myers Squibb and AstraZeneca jointly complained about cost comparison claims in a Lyxumia
More information